2:50 PM
Nov 13, 2018
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: B cell lymphoma

Cell and mouse studies suggest promoting PMAIP1 expression or inhibiting MCL1 could enhance the efficacy of BCL-2 inhibitors to treat diffuse large B cell lymphoma (DLBCL). In a DLBCL cell line, a tool compound BCL-2 inhibitor plus overexpression of PMAIP1, which binds MCL1 to promote apoptosis, increased cell death compared with...

Read the full 252 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >